Latest market price
18.98
-0.80-4.04%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -4.57 | Insider Own | 39.32% | Shs Outstand | 19.55M | Perf Week | -4.86% |
| Market Cap | 371.05M | Forward P/E | — | EPS next Y | -5.32 | Insider Trans | -0.01% | Shs Float | 10.17M | Perf Month | -15.79% |
| Enterprise Value | 147.05M | PEG | — | EPS next Q | -1.32 | Short Float | 21.88% | Perf Quarter | -34.93% | ||
| Income | -85.00M | P/S | — | EPS this Y | — | Short Ratio | 10.30 | Perf Half Y | -35.99% | ||
| Sales | 0.00 | P/B | 1.66 | EPS next Y | — | ROA | -36.19% | Short Interest | 2.22M | Perf YTD | -9.01% |
| Book/sh | 11.46 | P/C | 1.63 | EPS next 5Y | — | ROE | -35.26% | 52W High | 39.53 -51.99% | Perf Year | 7.84% |
| Cash/sh | 11.61 | P/FCF | — | EPS past 3/5Y | — | ROIC | -41.59% | 52W Low | 15.52 22.29% | Perf 3Y | 2.04% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 4.96% 5.35% | Perf 5Y | -70.98% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.25 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 22.29 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 27.56 | Recom | 1.80 |
| Dividend Gr. 3/5Y | — | Current Ratio | 22.29 | EPS Q/Q | -10.28% | SMA20 | -10.44% | Beta | 1.30 | Target Price | 62.33 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | — | SMA50 | -25.96% | Rel Volume | 0.83 | Prev Close | 19.78 |
| Employees | 60 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | -32.41% | Avg Volume | 221.50K | Price | 18.98 |
| IPO Date | Jun 21, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 12.51% — | Net Debt/EBITDA | — | Volume | 183,870 | Change | -4.04% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-11-26 | Initiated | UBS | Neutral | $26 |
| Sep-30-26 | Reiterated | Oppenheimer | ||
| May-26-26 | Upgrade | Raymond James | Outperform → Strong Buy | |
| Apr-13-26 | Initiated | Stifel | Buy | $75 |
| Jan-08-26 | Reiterated | Truist Securities | Buy | $60 |
Latest News· Times ET
Oct-21-26
Oct-21-2604:15AM
Oct-14-26
Oct-14-2603:02PM
Oct-12-26
Oct-12-2605:40AM
Sep-29-26
Sep-29-2608:00AM
Sep-26-26
Sep-26-2604:15AM
Sep-10-26
Sep-03-26
Sep-03-2608:00AM
Sep-02-26
Sep-02-2612:58AM
Aug-07-26
Aug-07-2601:58PM
Aug-06-26
Aug-06-2604:01PM
Company
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 22 | 21 | 17 | 8 | — | — | — | — | — | |
| Research and Development | 72 | 63 | 41 | 37 | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -95 | -84 | -58 | -45 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 10 | 11 | 0 | 2 | — | — | — | — | — | |
| Net Income Before Taxes | -85 | -73 | -58 | -43 | — | — | — | — | — | |
| Income Taxes | 0 | 1 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -85 | -74 | -58 | -43 | — | — | — | — | — | |
| Net Income From Continuing Operations | -85 | -74 | -58 | -43 | — | — | — | — | — | |
| Net Income | -85 | -74 | -58 | -43 | — | — | — | — | — | |
| EPS (Recurring) | -4.57 | -4.05 | -3.93 | -11.59 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.57 | -4.05 | -3.93 | -11.59 | — | — | — | — | — | |
| EPS (Diluted) | -4.57 | -4.05 | -3.93 | -11.53 | — | — | — | — | — | |
| EBITDA | -84 | -71 | -56 | -41 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 19 | 18 | 15 | 4 | — | — | — | — | — | |
| Market Capitalization | 361 | 375 | 693 | 65 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| REICIN ALISE | Chief Executive Officer | Oct 26 '26 | Option Exercise | 2.38 | 10,000 | 23,800 | 319,078 | Oct 28 |
| McNamara Peter | Chief Scientific Officer | Sep 30 '26 | Sale | 23.04 | 536 | 12,349 | 54,305 | Oct 02 |
| McNamara Peter | Chief Scientific Officer | Aug 25 '26 | Option Exercise | 14.71 | 43 | 633 | 55,328 | Aug 26 |
| McNamara Peter | Chief Scientific Officer | Aug 25 '26 | Sale | 36.52 | 43 | 1,570 | 55,285 | Aug 26 |
| McNamara Peter | Chief Scientific Officer | Aug 12 '26 | Option Exercise | 14.71 | 43 | 633 | 55,328 | Aug 14 |
| McNamara Peter | Chief Scientific Officer | Aug 12 '26 | Sale | 35.00 | 43 | 1,505 | 55,285 | Aug 14 |
| McNamara Peter | Chief Scientific Officer | Jun 30 '26 | Option Exercise | 14.71 | 172 | 2,530 | 55,457 | Jul 01 |
| McNamara Peter | Chief Scientific Officer | Jun 30 '26 | Sale | 35.00 | 172 | 6,020 | 55,285 | Jul 01 |
| Ruddy Marcella K. | Chief Medical Officer | May 04 '26 | Sale | 30.00 | 1,065 | 31,950 | 67,682 | May 06 |
| Ruddy Marcella K. | Chief Medical Officer | Apr 01 '26 | Sale | 31.05 | 1,000 | 31,050 | 68,747 | Apr 03 |
| Ruddy Marcella K. | Chief Medical Officer | Mar 06 '26 | Sale | 30.00 | 10,000 | 300,000 | 69,747 | Mar 09 |
| McNamara Peter | Chief Scientific Officer | Mar 06 '26 | Option Exercise | 3.36 | 2,715 | 9,113 | 61,547 | Mar 09 |
| McNamara Peter | Chief Scientific Officer | Mar 06 '26 | Sale | 30.17 | 6,262 | 188,935 | 55,285 | Mar 09 |
| McNamara Peter | Chief Scientific Officer | Mar 04 '26 | Sale | 25.00 | 1,650 | 41,250 | 58,832 | Mar 05 |
| McNamara Peter | Chief Scientific Officer | Mar 03 '26 | Sale | 22.06 | 1,649 | 36,377 | 37,482 | Mar 05 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.